The bill's implementation is expected to significantly alter state laws regarding health insurance by eliminating certain barriers in accessing vital medications for specific health conditions. By mandating that certain medications are exempt from step therapy requirements, healthcare providers may find it easier to prescribe appropriate treatments without having to navigate through prior authorization processes. Additionally, this may lead to improved health outcomes as patients can receive their medications more swiftly.
Summary
SB135 aims to amend existing regulations regarding step therapy protocols in health insurance policies. Specifically, it prohibits the use of prior authorization and step therapy requirements for medications treating autoimmune disorders, cancer, or substance use disorders unless a biosimilar, interchangeable biologic, or generic version is available. This change is intended to simplify access to necessary medications for patients with these serious health conditions, thereby improving their treatment process and adherence to prescribed therapies.
Sentiment
Supporters of SB135 express a positive sentiment towards the changes, citing the need to prioritize patient welfare and timely access to necessary treatments. They argue that the current step therapy requirements can lead to delays in care and negatively impact patient adherence. Conversely, some opposition exists from those concerned about potential increases in healthcare costs for insurers, fearing that removing these requirements could lead to higher claims without any cost-control measures in place.
Contention
Despite the perceived benefits of SB135, notable points of contention have emerged around the financial implications for insurers and the overall healthcare system. Some stakeholders argue that rushing the passage of such legislation without comprehensive cost analysis could result in unforeseen consequences, including increased premiums for consumers as insurers adjust their models to accommodate the new regulations. This ongoing debate highlights the tension between ensuring patient access to healthcare and managing the costs associated with such access.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.